Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

insulin U300 during the study period compared to the Lantus® group (45.3% vs. 59.7%; RR 0.76; 95% CI 0.66 to 0.87). New insulin U300 was well-tolerated in this study, with no differences in other adverse events observed from Lantus®.

The EDITION I abstract is titled: New Insulin Glargine Formulation: Glucose Control and Hypoglycemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I) (Riddle, MC et al) [Abstract no. 43-LB]EDITION II Topline results of EDITION II are consistent with EDITION I findings. EDITION II demonstrated that investigational new insulin U300 achieved similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

EDITION II evaluated efficacy and safety of new insulin U300 in a type 2 diabetes population (811 patients) treated with basal insulin plus oral antidiabetic therapy. The full EDITION II results will be submitted for presentation at upcoming scientific meetings.

"There remains a substantial unmet need in people with diabetes taking oral medication or insulin as many of them do not reach their glycemic goals," said Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "With the investigational new insulin U300, we are striving to further enhance the clinical value of basal insulin, while building on the wealth of evidence of Lantus®, the world's most prescribed insulin."

About investigational new insulin U300Investigational new insulin U300 is a new formulation based on the glargine molecule, the biological entity of Lantus®, with its well established efficacy and safety profile. However, new insulin U300 has unique pharmacokinetic and pharmacodynamic profiles with studies demonstrating it has even flatter and more prolonged profiles than Lantus®.1,2 New insulin U300 also offers the benef
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... 8, 2007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today announced ... improvements in patient-centered outcomes in,patients with diabetic ... drug Zenvia(TM) (dextromethorphan /,quinidine) will be presented ... Congress on Neuropathic Pain, being held in,Berlin, ...
... a Phase 2a,clinical trial evaluating the potential of NKTR-061 (inhaled,amikacin) ... the American Thoracic Society (ATS),International Conference, May 18 - 23, ... Dr. Michael S. Niederman, MD, Chairman, Department of, ... Professor of, ...
Cached Medicine Technology:AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... COLUMBIA, S.C., April 24 Choice Hotels,International (Choice) ... benefit health insurance plan from Planned Administrators Inc.,(PAI), ... hourly,employees nationwide., With the announcement, the franchisees ... brand hotels in the United States now have ...
... Best Non-Branded Web site, Best Branded ... Digital Media Campaign, WEST CONSHOHOCKEN, Pa., April 24 ... the healthcare,industry, announced today it recently received one silver ... dinner on Thursday, April 17,2008. Cadient Group campaigns were ...
... Calif., April 24 Accuray,Incorporated (Nasdaq: ARAY ), ... that its president and chief executive officer, Euan S.,Thomson, ... 2008 Global,Healthcare Unplugged Conference at the Ritz-Carlton in Key ... PDT (2:20 p.m. EDT)., A live webcast of ...
... Youthful ... Appearance, BEVERLY HILLS, Calif., ... Hills, CA states,"Changing the size and shape of your teeth can significantly ... patients,say that a smile make-over is better than botox in restoring a ...
... 24 UPMC Health Plan and Rainbow,Kitchen Community ... fourth,annual "W.A.R. (Walk and Ride) Against Hunger" on ... that supports Rainbow Kitchen,s,anti-hunger programs and services, and ... wellness., "W.A.R. Against Hunger" participants can either ...
... - Led by Reps. Tim Walz and Chris,Shays - ... Care,Key Caregiver Jobs Gains Support, WASHINGTON, April 24 ... as the potential loss of key front line,caregiver jobs ... national front line caregiver organization is praising U.S.,Reps. Tim ...
Cached Medicine News:Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 2Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 3Health News:Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards 2Health News:Accuray Incorporated's CEO to Present at Morgan Stanley 2008 Global Healthcare Unplugged Conference 2Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 3Health News:Nation's Front Line Caregivers Praise U.S. Representatives' Opposition to Medicare-Financed Nursing Home Care Cuts 2Health News:Nation's Front Line Caregivers Praise U.S. Representatives' Opposition to Medicare-Financed Nursing Home Care Cuts 3Health News:Nation's Front Line Caregivers Praise U.S. Representatives' Opposition to Medicare-Financed Nursing Home Care Cuts 4
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
... Micro Thin Sheet. Medpor Sheets are ... and other craniofacial applications. The thinner ... provide the surgeon with greater flexibility ... for easy insertion into the orbit. ...
... punching of the donor corneal button. ... with disposable trephine blades. Unique two ... of the donor tissue. Recessed base ... centrally under the trephine blade. Supplied ...
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Medicine Products: